Optimize canagliflozin doses – decrease hyperinsulinemia and prevent laminitis

Last changed: 30 March 2022

Horses with hyperinsuinemia are at risk to develop the painfuld condition laminitis. The drug canagliflozin has the potential to lower insulin levels and prevent laminitis.

Laminitis is a relatively common and very painful condition in horses. There is a strong correlation betweein elevated insulin levels in plasma and development of laminitis. In healthy horses insulin levels are kept at accepatable levels also after starch-rich meals, but not in horses with insulin dysregulation. Canagliflozin increases urinary glucose excretion which lowers insulin response. However, there is no information about how canagloflozin is absorbed from the stomach or at which rate it is eliminated from the horse. We also need more information about potential side-effects e.g. on liver or kidneys. This project aims at addressing those questions.

The project is planned to 2022 01 01 – 2024 12 31 and is funded by the Swedish-Norwegian Foundation for Equine Research.


Carl Ekstrand
Associate Senior Lecturer at the Department of Biomedical Science and Veterinary Public Health; Pharmacology and Toxicology Unit

Telephone: 018-673171
E-mail: carl.ekstrand@slu.se

Johan Bröjer
Professor at the Department of Clinical Sciences; Equine Medicine Unit

Telephone: 018-671388
E-mail: johan.brojer@slu.se

Inger Lilliehöök

Professor at the Department of Clinical Sciences; Clinical Pathology Unit                                    

Telephone: 018-671616
E-mail: inger.lilliehook@slu.se